Savara Inc. (Nasdaq: SVRA) announced that the European Patent Office has granted a patent covering the liquid formulation of Molbreevi, an investigational orally inhaled recombinant human GM-CSF being developed for autoimmune pulmonary alveolar proteinosis. European patent No. 4121000 provides protection through March 2041.

The Australian Patent Office separately granted patent No. 62/990,810 covering the same liquid formulation, also securing protection through March 2041.

In December 2025, Savara and PARI were granted a joint European patent covering the investigational drug-device combination of Molbreevi delivered via PARI's eFlow Nebulizer System, with protection extending through March 2043.

According to a statement from Savara's Chief Legal Officer Kate McCabe, the company is advancing equivalent patent filings in the U.S., including a patent for the drug-device combination, with the aim of securing protection across major commercial territories.

Molbreevi, which is not approved in any indication, has received Fast Track and Breakthrough Therapy Designations from the U.S. FDA, Orphan Drug Designation from both the FDA and the European Medicines Agency, and Innovation Passport and Promising Innovative Medicine designations from the U.K.'s Medicines and Healthcare Products Regulatory Agency for the treatment of autoimmune PAP. The drug is currently in Phase 3 development.